Scenic Immunology BV has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and/or glutaminyl-peptide cyclotransferase-like protein (QPCTL; isoQC) inhibitors reported to be useful for the treatment of cancer.

Hebei Wutu Pharmaceutical Co. Ltd. has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of liver cancer, cirrhosis, hepatic fibrosis, chronic hepatitis B and liver failure.

Nanjing Mingde New Drug Research Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.

Gruenenthal GmbH has patented new cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives acting as nociceptin receptor (OPRL1; KOR3; ORL1) agonists and thus reported to be useful for the treatment of pain.

Janssen Pharmaceutica NV has identified new compounds reported to be useful for the treatment of mycobacterial infections.

Sanofi SA has synthesized pyridoimidazolone compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.

Work at Horizon Omics Biotech Ltd. has led to the identification of quinolone derivatives reported to be useful for the treatment of cancer, autoimmune diseases, viral, bacterial and fungal infections.